Tao Synergies Inc (TAOX) Stock Price, Quote & News

Company Profile

TAO Synergies Inc. owns and operates an AI token. It focuses on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor and a decentralized blockchain network for machine learning and AI. The company was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. TAO Synergies Inc was incorporated in 2012 and is headquartered in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Phone: 973 242 0005

Website: taosynergies.com

Address:

1185 Avenue of the Americas, 3rd Floor, New York, United States

EndGame1 Aug. 29 at 2:59 AM

$TAOX Oh well... "Bittensor Drops 6.9% Amid $5.94M Token Unlock and AI Hype Recession Bittensor's price declined 6.9% over the past 24 hours to $236.41 following a reported $5.94M token unlock, which may have triggered short-term sell pressure. Despite ongoing ecosystem developments and endorsements, the unlock event aligns with the downward price movement."

0 · Reply

EndGame1 Aug. 28 at 1:18 PM

$TAOX "Bittensor Reframed as AI Infrastructure Token Amid Stake-for-Compute Proposals Analysts reframe Bittensor (TAO) as an AI infrastructure token. Proposals like "Conviction Lock" aim to link staked TAO to GPU compute access, potentially boosting demand for locked TAO."

0 · Reply

EndGame1 Aug. 28 at 1:15 AM

$TAOX "Bittensor Jumps 8% Following HTX Listing and Technical Breakout Confirmation Bittensor (TAO) saw an 8% price increase driven by its listing on HTX, increased staking activity, and confirmation of a technical breakout. HTX's listing boosted liquidity, while strong network participation and positive chart signals contributed to the upward momentum."

0 · Reply

EndGame1 Aug. 27 at 11:33 PM

$TAOX Looking good. Congrats to us longs that didn't give up on $TAO.X Bittensor TAO Price #41 $254.54 18.5% (7 day) .

0 · Reply

SnoopyPotter Aug. 27 at 11:10 PM

post from James Altucher : At $TAOX, the largest public holder of $TAO.X tokens, we are super bullish. A) $TAO.X is the largest decentralized AI platform. B) $TAO.X is like an ETF of 128 AI state-of-the-art subnets. C)@const and the other developers on TAO have immense integrity. D) $TAO.X (with 128 valuable companies) has only a $3B market cap vs companies like OpenAI with $1.5Trillion in value. E) $TAO.X is evolving and will become only better with time, through governance and advances in tech. $TAO.X is not a crypto but an AI platform that is succeeding and under-noticed. $TAOX is the public vehicle to invest in TAO. We are invested in $TAO.X , the subnets, and own the largest media outlet about TAO, the @taodaily_io as well as public-facing front-end into TAO inference : http://BlueTAO.ai

1 · Reply

SilentRider1 Aug. 27 at 10:16 PM

$TAOX

0 · Reply

EndGame1 Aug. 27 at 6:33 PM

$TAOX @ jaltucher X "At $TAOX , the largest public holder of Bittensor tokens, we are super bullish. A) TAO is the largest decentralized AI platform. B) is like an ETF of 128 AI state-of-the-art subnets. C) @ const and the other developers on TAO have immense integrity. D) $TAO.X (with 128 valuable companies) has only a $3B market cap vs companies like OpenAI with $1.5TRILLION in value. E) is evolving and will become only better with time, through governance and advances in tech. TAO is not a crypto but an AI platform that is succeeding and under-noticed. TAO is the public vehicle to invest in TAO. We are invested in TAO, the subnets, and own the largest media outlet about TAO, the @ taodaily_io as well as public-facing front-end into TAO inference : http://BlueTAO.ai

0 · Reply

EndGame1 Aug. 27 at 1:51 PM

$TAOX It's a small company, but every $1 $TAO.X goes up, their coin value goes up $83,000. And that's not counting their Bittensor staking. Bittensor TAO Price $256.59 23.1% (7d)

1 · Reply

EndGame1 Aug. 27 at 1:35 PM

$TAOX It's happening for $TAO https://www.coingecko.com/en/coins/bittensor?chart=type%3Dprice%26mode%3Dline%26timeframe%3Dd7

0 · Reply

JohnnyP5 Aug. 27 at 8:13 AM

$TAOX

0 · Reply

TAO Synergies appoints Jeffrey as an advisor to the Company

Jul 8, 2026, 9:15 AM EDT - 7 weeks ago

TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor

2026-06-16T13:21:36.000Z - 2 months ago

TAO Synergies to join the Russell Microcap Index

Jun 16, 2026, 9:15 AM EDT - 2 months ago

TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI

Nov 18, 2025, 5:15 PM EST - 10 months ago

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

BEX CSEX NNEX SNPX

Nov 18, 2025, 9:15 AM EST - 10 months ago

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Nov 13, 2025, 6:46 AM EST - 10 months ago

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

BEX CSEX NNEX SNPX

2025-11-12T21:22:16.000Z - 10 months ago

TAO Synergies files to sell 22.3M shares of common stock for holders

Nov 11, 2025, 11:26 AM EST - 10 months ago

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

BEX CSEX NNEX SNPX

2025-11-04T14:20:39.000Z - 10 months ago

TAO Synergies announces initial $750K investment in Bittensor Subnet Funds

Nov 4, 2025, 9:15 AM EST - 10 months ago

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

2025-10-20T13:20:22.000Z - 11 months ago

TAO Synergies reports total TAO increased to 54,058 tokens

Oct 20, 2025, 9:15 AM EDT - 11 months ago

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

2025-10-13T21:15:14.000Z - 11 months ago

TAO Synergies announces $11M private placement

Oct 13, 2025, 5:09 PM EDT - 11 months ago

TAO Synergies Announces $11 Million Private Placement

Sep 22, 2025, 9:15 AM EDT - 1 year ago

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

Sep 8, 2025, 9:15 AM EDT - 1 year ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Aug 26, 2025, 9:15 AM EDT - 1 year ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

2025-08-14T20:55:13.000Z - 1 year ago

TAO Synergies files $100M mixed securities shelf

2025-07-17T13:21:08.000Z - 1 year ago

TAO Synergies acquires $10M of Bittensor

2025-07-11T21:05:08.000Z - 1 year ago

TAO Synergies files to sell 5.04M shares of common stock for holders

Jul 1, 2025, 9:15 AM EDT - 1 year ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jun 26, 2025, 9:15 AM EDT - 1 year ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 24, 2025, 9:15 AM EDT - 1 year ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 9, 2025, 9:00 AM EDT - 1 year ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Dec 20, 2024, 9:15 AM EST - 1 year ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Sep 11, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces $5.0 Million Financing

Jul 18, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jun 26, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

May 7, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Apr 24, 2024, 9:15 AM EDT - 2 years ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Dec 19, 2023, 9:00 AM EST - 2 years ago

Synaptogenix President Daniel L. Alkon, M.D.

Dec 6, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Nov 2, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Sep 26, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 7, 2023, 9:00 AM EDT - 3 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Jul 19, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 13, 2023, 9:00 AM EDT - 3 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Mar 7, 2023, 9:00 AM EST - 3 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Dec 16, 2022, 9:00 AM EST - 4 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Nov 18, 2022, 9:00 AM EST - 4 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Oct 19, 2022, 9:00 AM EDT - 4 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Sep 28, 2022, 11:50 AM EDT - 4 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Aug 12, 2022, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Jul 26, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 21, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Announces Corporate Update Conference Call

Jul 20, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

May 17, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at the Cell Symposium

Apr 19, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 5, 2022, 9:15 AM EDT - 4 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Mar 29, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 22, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 15, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Feb 23, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 1, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Sep 10, 2021, 9:00 AM EDT - 5 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Aug 5, 2021, 10:00 AM EDT - 5 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Jul 26, 2021, 9:15 AM EDT - 5 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

EndGame1 Aug. 29 at 2:59 AM

0 · Reply

EndGame1 Aug. 28 at 1:18 PM

0 · Reply

EndGame1 Aug. 28 at 1:15 AM

0 · Reply

EndGame1 Aug. 27 at 11:33 PM

$TAOX Looking good. Congrats to us longs that didn't give up on $TAO.X Bittensor TAO Price #41 $254.54 18.5% (7 day) .

0 · Reply

SnoopyPotter Aug. 27 at 11:10 PM

1 · Reply

SilentRider1 Aug. 27 at 10:16 PM

$TAOX

0 · Reply

EndGame1 Aug. 27 at 6:33 PM

0 · Reply

EndGame1 Aug. 27 at 1:51 PM

$TAOX It's a small company, but every $1 $TAO.X goes up, their coin value goes up $83,000. And that's not counting their Bittensor staking. Bittensor TAO Price $256.59 23.1% (7d)

1 · Reply

EndGame1 Aug. 27 at 1:35 PM

$TAOX It's happening for $TAO https://www.coingecko.com/en/coins/bittensor?chart=type%3Dprice%26mode%3Dline%26timeframe%3Dd7

0 · Reply

JohnnyP5 Aug. 27 at 8:13 AM

$TAOX

0 · Reply

EndGame1 Aug. 27 at 1:45 AM

$TAOX We know we've made it when Bittensor goes up but Bitcoin doesn't.

0 · Reply

EndGame1 Aug. 26 at 1:58 PM

$TAOX Mark Jeffrey @ markjeffrey on X had a twitter space last night about $TAO.X . He said more to come. Maybe a couple/week. 690 folks tuned in. Bittensor is finally getting noticed.

0 · Reply

EndGame1 Aug. 25 at 4:16 PM

$TAOX Jason Calacanis on X to a poster. He said he thinks BTC may have peaked for now, but TAO hasn’t. Here’s his reply… “I’m long $TAO.X … but only because it has amazing entrepreneurial energy in the subnets solving a large array of real-world problems You should buy one $TAO.X — not financial advice, buy it to support AI sovereignty”

0 · Reply

EndGame1 Aug. 25 at 3:28 PM

$TAOX is my number two holding. OT...Not many posters here, but here's a data center stock tip $SLNH I made it my number four holding in my portfolio. Very smart management. Trading at $1.26. You can get a lot of shares at that price. They have 6.3GW potential. They have the land and power, but no AI contract yet, but it's imminent. $DGXX is my third largest holding. They will also double, but it's $4 . They are a year ahead of Soluna. Soluna can go to $5.

0 · Reply

EndGame1 Aug. 25 at 1:41 PM

$TAOX Thin to ten. The last price I sold.

0 · Reply

EndGame1 Aug. 24 at 4:41 PM

$TAOX Every day a new subnet comes out with something new. Why Jason loves $TAO.X "Bittensor's Teutonic subnet trains 110B LLM, building on previous successes. The Teutonic subnet has announced the training of Teutonic-II-110B, a 110 billion parameter LLM, significantly larger than previous decentralized models. This follows recent subnet successes including a 72B parameter model and a commercial drone contract."

0 · Reply

EndGame1 Aug. 24 at 3:16 PM

$TAOX $247 was $TAO.X weekend high.

0 · Reply

EndGame1 Aug. 24 at 1:46 PM

$TAOX $TAO.X $238 "Bittensor Subnets Secure Commercial Contract and Execute TAO Buyback Swarm Subnet (SN124) secured its first commercial drone surveillance contract, while subnet SN51 completed a 2,500 TAO buyback funded by GPU revenue. These developments signal growing real-world adoption and positive tokenomics for Bittensor.

0 · Reply

EndGame1 Aug. 24 at 1:30 PM

$TAOX I said $5/share last week. It's coming.

0 · Reply

EndGame1 Aug. 21 at 8:01 PM

$TAOX A good day. Maybe we hold $4 Monday?

2 · Reply

EndGame1 Aug. 21 at 5:31 PM

$TAOX Jason Calacanis told everone to just buy at least one $TAO.X coin at $190/coin, because it could do what $BTC.X did from the start.

1 · Reply

EndGame1 Aug. 21 at 5:09 PM

$TAOX $230. It's been 2 months since we've been here. Bittensor TAO Price #42 $230.58 17.6% (7d)

0 · Reply

Market Cap	32.03M
Revenue (ttm)	300,000.00
Net Income (ttm)	-28.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-9,580.00%
Debt to Equity Ratio	0.00

Volume	182,300
Avg Vol	110,638
Day's Range	N/A - N/A
Shares Out	7.48M
Stochastic %K	58%
Beta	1.45
Analysts	Strong Buy
Price Target	N/A